Perspective Therapeutics (CATX) Income towards Parent Company (2010 - 2026)

Perspective Therapeutics has disclosed Income towards Parent Company across 17 years of filings, most recently posting -$26.2 million for Q1 2026.

• Income towards Parent Company for Q1 2026 came in at -$26.2 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was -$25.7 million (down 5139.8% YoY), and the FY2025 annual result was $514000.0, up 154.16% from the prior year.
• Income towards Parent Company came in at -$26.2 million for Q1 2026 at Perspective Therapeutics, down from $514000.0 in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $514000.0 in Q2 2025 to a low of -$26.2 million in Q1 2026.
• The 5-year median for Income towards Parent Company is -$1.5 million (2023), against an average of -$3.8 million.
• Across the five-year window, Income towards Parent Company sank 254.38% in 2022 and surged 204.9% in 2025, its largest moves.
• Perspective Therapeutics' Income towards Parent Company stood at -$2.3 million in 2022, then slumped by 127.82% to -$5.2 million in 2023, then jumped by 90.55% to -$490000.0 in 2024, then soared by 204.9% to $514000.0 in 2025, then plunged by 5195.14% to -$26.2 million in 2026.
• The last three Income towards Parent Company figures came in at -$26.2 million (Q1 2026), $514000.0 (Q2 2025), and -$490000.0 (Q2 2024), per Business Quant data.